A Retrospective Study Investigating Effect of Dual versus Monotherapy Inhaled Corticosteroids on Outcomes of Pneumonia among COPD Patients

Ho KM (1), Yeung WC (1)
(1) Department of Pharmacy, North District Hospital

Keywords:
Pneumonia
COPD
Inhaled Corticosteroids

Introduction
In North District Hospital (NDH), dual therapy of Inhaled Corticosteroids (ICS) in COPD patients is common but not a recommendation in 2015 GOLD guideline.

Objectives
We wanted to study the effect of dual ICS on outcomes of pneumonia among COPD patients.

Methodology
This was a retrospective study. Patients with diagnosis of COPD and pneumonia during the period from 01-01-2011 to 31-12-2013 in NDH were recruited. Patients with continuous use of 6 months ICS were included while those with concomitant diagnosis of asthma or use of systemic steroids within 4 weeks before admission were excluded. Each patient profile was accessed and relevant data were recorded. Relevant data were baseline characteristics, comorbidities, usage of medications, and outcome measurements which included 30-day, 90-day mortality as primary end-point, and use of mechanical ventilation as secondary end-point.

Result
242 patients using monotherapy of ICS and 109 patients using dual therapy of ICS were included in this study. In 30-day mortality, more patients died in dual therapy group (monotherapy 11.6% vs dual ICS 16.5%; p-value=0.204). In 90-day mortality, more patients died in dual therapy group (monotherapy 7.0% vs dual ICS 13.8%; p-value=0.042) and this difference was statistically significant. In use of mechanical ventilation, there were more patients in dual therapy group. (monotherapy 5.8% vs dual therapy 18.3%; p-value<0.001) and this difference was statistically significant. After doing statistical adjustment using logistic regression analysis, only use of mechanical ventilation outcome reached statistical significance. (30-day mortality: OR: 2.264; 95%CI 0.931-5.507; p-value=0.072; 90-day mortality: OR: 2.744; 95%CI 0.992-7.594; p-value=0.052; Use of mechanical ventilation: OR: 5.55; 95%CI: 2.118-14.569; p-value<0.001) Dual ICS therapy increases risk of worse pneumonia outcomes among COPD patients. Compliance to different inhalers is a
problem to patients and if dual ICS therapy increases risk of worse pneumonia outcome, we should not recommend this practice.